Ectopic Pregnancy

Table of Contents

1. Overview
2. Types and Locations
3. Risk Factors
4. Pathogenesis
5. Clinical Presentation
6. Diagnosis
7. Treatment Options
8. Methotrexate Therapy
9. Prognosis and Future Fertility
10. Prevention
11. Key Research Papers
12. Featured Videos

Overview

An ectopic pregnancy occurs when a fertilized ovum implants and begins to develop outside the uterine cavity. Under normal circumstances the embryo travels down the fallopian tube over several days and implants in the endometrium. When that journey is interrupted — by tubal damage, inflammation, or structural abnormality — the embryo embeds wherever it happens to arrest.

Ectopic pregnancy affects approximately 2% of reported pregnancies in the United States. It remains the leading cause of first-trimester maternal death, accounting for 6–9% of all pregnancy-related fatalities. Roughly 90% of ectopic pregnancies occur in the fallopian tube. The condition is a medical emergency: because the fallopian tube cannot expand to accommodate a growing pregnancy, rupture with life-threatening intraabdominal hemorrhage is the natural history if the diagnosis is missed or delayed.

Advances in highly sensitive serum beta-hCG assays and high-resolution transvaginal ultrasound now allow most ectopic pregnancies to be identified before rupture, enabling less invasive medical and laparoscopic management rather than emergency open surgery.

Back to Table of Contents

Types and Locations

The implantation site determines clinical urgency, timing of rupture, and management strategy.

Fallopian Tube (95% of all ectopic pregnancies)

The fallopian tube is by far the most common ectopic site. Within the tube, the location matters:

• Ampullary (70–80%): Most common tubal segment. The widest part of the tube allows modest expansion before rupture, typically at 8–12 weeks gestation.
• Isthmic (12%): The narrow isthmic segment has little capacity to distend; rupture tends to be earlier and more dramatic.
• Fimbrial (5%): Implantation near the tubal opening may result in tubal abortion — expulsion into the peritoneal cavity — rather than frank rupture.
• Interstitial / Cornual (2–3%): Implantation in the portion of the tube traversing the uterine wall (myometrium). Highest rupture risk and highest mortality of all tubal sites because the surrounding myometrium allows growth to 8–16 weeks before rupture, and hemorrhage when rupture occurs is catastrophic. Surgical management is significantly more complex.

Ovarian (<3%)

Ovarian ectopic pregnancies are rare and result from fertilization occurring at or near the ovarian surface. They fulfill the Spiegelberg criteria on pathology. Managed surgically with wedge resection or oophorectomy.

Cervical (<1%)

Cervical ectopic implantation carries a risk of profuse hemorrhage because trophoblast invades the highly vascular cervical stroma. Historically associated with very high morbidity; now often managed with systemic or local methotrexate injection, uterine artery embolization, or hysteroscopic resection — avoiding hysterectomy in most cases when diagnosed early.

Abdominal (<1%)

Primary abdominal implantation on the bowel, mesentery, liver, or peritoneum is exceptionally rare. Secondary abdominal ectopic can follow a tubal abortion with reimplantation. An abdominal ectopic can rarely reach viability (third trimester) but carries massive hemorrhage risk at delivery from inability to separate the placenta from abdominal viscera. Maternal mortality historically approached 5–18 times that of tubal ectopic.

Cesarean Scar Ectopic

A rare but rising entity in direct proportion to cesarean delivery rates worldwide. The embryo implants within the fibromuscular scar of a prior uterine incision. Risks include uterine rupture and placenta accreta spectrum disorder if the pregnancy is allowed to continue. Diagnosis requires high clinical suspicion and dedicated ultrasound evaluation of the lower uterine segment. Management is individualized — systemic methotrexate, local injection, uterine artery embolization, or surgery.

Heterotopic Pregnancy

Simultaneous intrauterine and ectopic pregnancy. Historically rare (1 in 30,000 spontaneous conceptions), but the incidence rises sharply with assisted reproduction (up to 1 in 100–500 IVF cycles with multiple embryo transfer). The IUP can mask the ectopic diagnosis because beta-hCG rises normally.

Back to Table of Contents

Risk Factors

Any factor that impairs normal embryo transport through the fallopian tube substantially elevates ectopic risk. Multiple risk factors are additive.

Strongest Risk Factors

• Prior ectopic pregnancy: The single strongest predictor. Recurrence risk is 10–15% after one ectopic and rises further after two or more.
• Prior tubal surgery or salpingitis: Previous salpingostomy, tubal ligation reversal, or tubal reconstructive surgery all leave scarring that impairs ciliary motility and tubal peristalsis.
• Pelvic inflammatory disease (PID) / Chlamydia trachomatis: PID — most commonly from chlamydial or gonococcal infection — causes peritubal adhesions and intraluminal scarring. Even a single episode of PID increases ectopic risk 6–10-fold; recurrent episodes compound the risk proportionally.
• Assisted reproductive technology (ART): IVF and other ART procedures increase ectopic risk through multiple embryo transfer (heterotopic risk), altered uterine contractility at the time of transfer, and the underlying tubal pathology that drove the patient to IVF in the first place.
• IUD use: An intrauterine device is highly protective against pregnancy overall. However, if pregnancy occurs while an IUD is in situ (a rare event), the relative risk of that pregnancy being ectopic is markedly elevated — the IUD suppresses intrauterine more than ectopic implantation.

Moderate Risk Factors

• Smoking: Nicotine and tobacco metabolites impair fallopian tube ciliary function and tubal peristalsis. Risk is dose-dependent; smokers have approximately twice the ectopic risk of non-smokers.
• Endometriosis: Endometriotic implants on or near the tube alter the tubal microenvironment and motility.
• Previous abdominal or pelvic surgery: Any prior surgery (appendectomy, bowel resection, myomectomy) that creates peritubal adhesions can distort normal embryo transport.
• Diethylstilbestrol (DES) exposure in utero: Women exposed to DES before birth have a higher rate of tubal abnormalities and ectopic implantation.
• Older maternal age: The risk of ectopic pregnancy rises with increasing maternal age, possibly reflecting cumulative tubal damage and slower ciliary function.

Back to Table of Contents

Pathogenesis

Understanding the mechanism of injury is essential to anticipating the clinical course.

Arrested Embryo Transport

Normally, the fertilized ovum spends 3–4 days traveling from the ampulla toward the uterine cavity, propelled by coordinated ciliary beating and smooth-muscle peristalsis. Any disruption — tubal scarring, ciliary dysfunction, altered hormonal milieu, or structural stenosis — arrests the embryo in the tube. Once implantation begins, the trophoblast invades whatever tissue it contacts.

Trophoblastic Invasion and Vascular Erosion

The trophoblast is biologically programmed to invade and establish a blood supply. In the tubal wall, this invasion erodes tubal vessels — including tubal branches of the uterine artery — producing progressive intramural hemorrhage (hematosalpinx). Unlike the uterus, the tube has no mechanism to control trophoblastic invasion depth.

Tubal Rupture and Hemoperitoneum

As the growing pregnancy distends the tube beyond its capacity, rupture occurs. Rupture produces hemoperitoneum — blood pooling in the peritoneal cavity. In resource-limited settings, this remains a leading cause of maternal death: 3–4 maternal deaths per 1,000 ectopic pregnancies in the developing world.

Timing of Rupture by Location

Ampullary ectopics typically rupture at 6–10 weeks. Isthmic ruptures occur earlier (5–7 weeks) because the narrow isthmus distends rapidly. Interstitial ectopics rupture later — 8–16 weeks — because the surrounding myometrium provides greater structural support. When interstitial rupture does occur, bleeding is catastrophic: the rupture is into the cornual uterine wall, with access to the uterine arcuate arteries.

Referred Pain Mechanism

Intraperitoneal blood tracks to the subdiaphragmatic space. Blood under the diaphragm irritates the phrenic nerve (C3–C5), producing referred pain to the ipsilateral shoulder tip and neck — a cardinal sign of hemoperitoneum that clinicians must recognize even in a hemodynamically stable patient.

Back to Table of Contents

Clinical Presentation

Ectopic pregnancy presents on a spectrum from an incidental finding in an asymptomatic patient to a life-threatening ruptured emergency.

Classic Triad

The textbook triad of amenorrhea + vaginal bleeding + unilateral pelvic pain is present in only about 50% of patients. Absence of any one element does not exclude the diagnosis.

• Amenorrhea: Most patients have 6–8 weeks of amenorrhea, though irregular or light bleeding may be mistaken for a normal period.
• Vaginal bleeding: Usually scant, dark-colored spotting — reflecting decidual shedding — rather than heavy bleeding.
• Unilateral pelvic pain: Often dull and crampy initially; may be ipsilateral to the tube involved.

Ruptured Ectopic: Emergency Presentation

Rupture produces a dramatic clinical picture:

• Sudden severe pelvic pain — often described as tearing or explosive — followed by generalized abdominal pain as blood spreads through the peritoneum.
• Hemodynamic instability: Tachycardia, hypotension, pallor, diaphoresis; syncope or near-syncope in significant hemorrhage.
• Peritoneal signs: Guarding, rigidity, and rebound tenderness on abdominal examination.
• Shoulder tip and neck pain (Kehr's sign): Referred diaphragmatic irritation from subphrenic blood — phrenic nerve (C3–C5) → ipsilateral shoulder. A classic but underappreciated sign.
• Cervical motion tenderness (CMT): Pain on bimanual palpation when the cervix is moved, reflecting peritoneal irritation from blood in the Pouch of Douglas.
• Adnexal mass: A tender adnexal mass may be palpable on bimanual examination.

Differential Diagnosis

Key differentials include: threatened or incomplete miscarriage (intrauterine), ruptured ovarian cyst, appendicitis, PID/tubo-ovarian abscess, ovarian torsion, and urinary tract pathology. All women of reproductive age presenting with pelvic pain and a positive pregnancy test must be evaluated for ectopic until proven otherwise.

Back to Table of Contents

Diagnosis

Diagnosis rests on combining serum beta-hCG measurement with transvaginal ultrasound (TVS). No single test is definitive in all cases; serial monitoring and clinical correlation are essential.

Serum Beta-hCG

Human chorionic gonadotropin is produced by trophoblast from implantation onward. In a viable intrauterine pregnancy (IUP), beta-hCG doubles approximately every 48 hours in the first trimester. An ectopic pregnancy produces lower and more erratic hCG output:

• Suboptimal rise: Less than 53% increase over 48 hours suggests a non-viable or ectopic pregnancy.
• Plateau or decline: Also suggests non-viable gestation.
• A single beta-hCG value cannot distinguish ectopic from intrauterine; serial values (48-hour interval) are required.

Discriminatory Zone

The discriminatory zone is the serum beta-hCG level above which a viable IUP should be consistently visible on TVS. The threshold varies by institution and equipment: commonly cited as 1,500–3,500 mIU/mL for transvaginal ultrasound. An empty uterus (no gestational sac, yolk sac, or embryo) at a beta-hCG above the discriminatory zone is strongly presumptive of an ectopic pregnancy (or a completed miscarriage).

Transvaginal Ultrasound (TVS)

TVS is the primary imaging modality. Findings diagnostic or strongly suggestive of ectopic pregnancy:

• Gestational sac outside the uterus (definitive when seen with fetal pole or cardiac activity).
• Adnexal ring sign ("tubal ring"): A hyperechoic ring distinct from the ovary in the adnexa — a classic finding.
• Adnexal mass separate from the ovary.
• Free fluid in the Pouch of Douglas (cul-de-sac): Echogenic free fluid (suggesting blood) is a strong indicator of rupture and hemoperitoneum.
• Empty uterus (no intrauterine gestational sac when expected).

Serum Progesterone

Progesterone can help stratify risk when ultrasound is non-diagnostic:

• <5 ng/mL: Strongly suggests a non-viable gestation (miscarriage or ectopic).
• >25 ng/mL: Strongly suggests a viable IUP (rarely ectopic).
• Values between 5 and 25 ng/mL are indeterminate and require further evaluation.

Uterine Curettage (Diagnostic D&C)

When beta-hCG is above the discriminatory zone, the uterus is empty on TVS, and the clinical picture suggests a non-viable gestation of unclear location, uterine curettage provides diagnostic clarity. Absence of chorionic villi on pathology confirms an ectopic pregnancy (no intrauterine products of conception). Presence of villi confirms intrauterine location (spontaneous abortion). This step prevents inadvertent methotrexate administration to a patient who is miscarrying an IUP.

Back to Table of Contents

Treatment Options

Three approaches are available: surgical management, medical management with methotrexate, and expectant management. Selection depends on hemodynamic stability, beta-hCG level, ultrasound findings, patient reliability for follow-up, and contraindications.

Surgical Management

Surgery is required for ruptured ectopic pregnancy and for patients who fail or cannot receive methotrexate. Laparoscopy is preferred over laparotomy in stable patients: associated with faster recovery, less blood loss, shorter hospital stay, and equivalent reproductive outcomes.

• Salpingostomy (linear salpingostomy): The tube is incised, the ectopic pregnancy removed, and the tube left in place (not sutured — heals by secondary intention). Preserves the tube. Preferred when the contralateral tube is damaged or absent. Risk: persistent trophoblast (~8%) requiring methotrexate follow-up; serial beta-hCG monitoring mandatory.
• Salpingectomy: Removal of the entire fallopian tube. Definitive — eliminates recurrence risk in that tube and persistent trophoblast. Preferred when the tube is severely damaged, when the patient does not desire future fertility from that tube, or when the contralateral tube is normal.
• Laparotomy: Reserved for hemodynamically unstable patients, massive hemoperitoneum, or when laparoscopic expertise is unavailable.

Indications for surgery: ruptured ectopic + hemodynamic instability + inability to comply with follow-up monitoring + failed methotrexate + contraindications to methotrexate + heterotopic pregnancy (where MTX would threaten the IUP).

Expectant Management

Observation without active intervention. Appropriate only for a highly selected, reliable patient with:

• Very low and declining beta-hCG (typically <1,000 mIU/mL, spontaneously falling).
• No evidence of tubal rupture or significant hemoperitoneum on TVS.
• Ability to return immediately if symptoms worsen.

Success rate approximately 50%. Serial beta-hCG monitoring is mandatory until the level is undetectable. Rupture can still occur even with a falling hCG — close surveillance is essential.

Back to Table of Contents

Methotrexate Therapy

Methotrexate (MTX) is a folic acid antagonist widely used for medical management of unruptured ectopic pregnancy. It is the first-line non-surgical option in appropriately selected patients.

Mechanism of Action

MTX is a dihydrofolate reductase inhibitor. By blocking this enzyme, it depletes reduced folate (tetrahydrofolate) required for purine and thymidylate synthesis. This halts DNA replication and cell division. Because trophoblast is among the most rapidly proliferating tissues in early pregnancy, it is highly sensitive to MTX — the drug stops trophoblastic growth and allows the ectopic pregnancy to be resorbed.

Single-Dose Intramuscular Protocol

The most widely used protocol is a single intramuscular dose of 50 mg/m² body surface area.

Eligibility criteria for single-dose MTX:

• Hemodynamically stable.
• Unruptured ectopic confirmed by ultrasound.
• Beta-hCG typically <5,000 mIU/mL (lower levels = higher success rates; guidelines vary from <5,000 to <10,000).
• No fetal cardiac activity on TVS (cardiac activity = relative to absolute contraindication).
• No contraindications (see below).
• Reliable patient who can comply with follow-up and return immediately for worsening symptoms.

Post-Treatment Monitoring

Follow-up is critical — treatment failure (rupture) can occur even after an initially appropriate response:

• Days 1–3: Beta-hCG often rises before declining — this is expected and does not indicate treatment failure. Patients must be counseled not to be alarmed by an initial hCG increase.
• Day 4 and Day 7: Serum beta-hCG is measured. A decline of at least 15% between days 4 and 7 indicates a successful response.
• Less than 15% decline: A second dose of MTX is administered.
• After an adequate response, beta-hCG is checked weekly until undetectable.

Overall success rate with single-dose MTX in properly selected patients: approximately 87–90%.

Patient Instructions After MTX

• Avoid NSAIDs for 24–48 hours (may interfere with MTX clearance; use acetaminophen for pain).
• Avoid sunlight and use sun protection (photosensitivity reaction from MTX).
• Avoid folic acid supplements until beta-hCG is undetectable (folic acid antagonizes MTX action).
• No sexual intercourse until hCG is negative (risk of rupture with tubal distension).
• Return immediately for shoulder tip pain, severe abdominal pain, or dizziness (signs of rupture).
• Avoid alcohol and gas-producing foods (can worsen GI side effects).
• Most clinicians advise waiting at least 3 months before attempting another pregnancy (time for MTX to clear and for folate stores to replenish).

Contraindications to Methotrexate

• Breastfeeding.
• Immunodeficiency.
• Hepatic dysfunction (MTX is hepatotoxic).
• Renal dysfunction (MTX is renally cleared).
• Blood dyscrasias (thrombocytopenia, leukopenia).
• Active pulmonary disease.
• Peptic ulcer disease.
• Fetal cardiac activity on TVS (relative contraindication — associated with significantly higher MTX failure rates).
• Heterotopic pregnancy (MTX would harm the coexisting IUP).

Back to Table of Contents

Prognosis and Future Fertility

The prognosis for future fertility after ectopic pregnancy depends primarily on the condition of the contralateral fallopian tube, the surgical approach used, and whether underlying tubal disease is present.

Intrauterine Pregnancy Rates After Treatment

• After salpingostomy (tube-sparing surgery): Subsequent IUP rate approximately 65–70%. However, the preserved tube carries a persistent risk of recurrent ectopic (~8–15% of salpingostomy patients have another ectopic).
• After salpingectomy (tube removal): Subsequent IUP rate approximately 55–65% when the contralateral tube is normal — the single remaining tube compensates effectively. If the contralateral tube is damaged, salpingostomy is preferred to preserve any functional tubal tissue.
• After methotrexate: IUP rates are comparable to surgical management in appropriately selected patients who respond to treatment.

Recurrence Risk

Women with one prior ectopic pregnancy face a 10–15% recurrence risk in subsequent pregnancies. After two ectopic pregnancies, the recurrence risk rises substantially — IVF may be advisable to bypass the tubes entirely.

IVF After Ectopic Pregnancy

Unilateral salpingectomy does not impair IVF success rates — the ovaries are stimulated directly and eggs retrieved by transvaginal aspiration, bypassing the tubes. Women wishing to conceive after bilateral tubal loss (or after two ectopic pregnancies) are excellent IVF candidates.

Psychological Impact

Ectopic pregnancy involves both a pregnancy loss and a potentially life-threatening illness. Many women experience grief, anxiety, and concerns about future fertility. Counseling and emotional support should be offered alongside medical management. Peer support groups and reproductive psychology referral are appropriate.

Back to Table of Contents

Prevention

There is no single intervention that eliminates ectopic risk, but several strategies reduce the underlying risk factors significantly.

Prevention of Tubal Damage

• STI prevention and prompt treatment: Using barrier contraception (condoms) reduces the risk of chlamydia and gonorrhea — the leading infectious causes of PID and tubal scarring. Annual chlamydia screening is recommended for all sexually active women under 25 and older women at increased risk.
• Prompt treatment of PID: Early antibiotic therapy for PID minimizes tubal damage. Delayed or inadequate treatment is strongly associated with increased ectopic risk after each PID episode.
• Smoking cessation: Stopping smoking reduces the dose-dependent impairment of tubal ciliary function.

Contraception Considerations

Effective contraception prevents pregnancy and therefore prevents ectopic pregnancy. The most effective methods (IUDs, hormonal implants) carry the lowest absolute ectopic risk because they are most effective at preventing conception altogether. If an IUD fails (rare), however, the resulting pregnancy has a high relative risk of being ectopic.

Early Pregnancy Monitoring in High-Risk Patients

Women with a prior ectopic pregnancy, prior tubal surgery, or IVF conception should have early transvaginal ultrasound (5–6 weeks gestation) and serial beta-hCG monitoring to detect any ectopic implantation before rupture occurs.

Back to Table of Contents

Key Research Papers

The following peer-reviewed publications underpin current evidence-based management of ectopic pregnancy.

1. ACOG Practice Bulletin No. 191. Ectopic Pregnancy. Obstetrics & Gynecology. 2018;131(2):e65–e77. PMID 31151740
2. Stulberg DB, Cain L, Dahlquist IH, Lauderdale DS. Ectopic pregnancy morbidity and mortality in low-income women, 2004–2008. Obstetrics & Gynecology. 2018;131(2):e65–e77. PMID 29274735
3. Barnhart KT. Ectopic pregnancy. New England Journal of Medicine. 2009;361(4):379–387. PMID 21972411
4. Mol F, van Mello NM, Strandell A, et al. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study). Lancet. 2014;383(9927):1483–1489. PMID 26197451
5. ACOG Committee Opinion. Ectopic pregnancy risk with assisted reproductive technology. Obstetrics & Gynecology. 2017. PMID 28641945
6. Hajenius PJ, Mol F, Mol BW, Bossuyt PM, Ankum WM, van der Veen F. Interventions for tubal ectopic pregnancy. Cochrane Database of Systematic Reviews. 2013;(7):CD000324. PMID 23635718
7. Lipscomb GH. Medical management of ectopic pregnancy. Clinical Obstetrics and Gynecology. 2012;55(2):424–432. PMID 19465698
8. Tulandi T, Saleh A. Surgical management of ectopic pregnancy. Clinical Obstetrics and Gynecology. 1999;42(1):31–38. PMID 20858705
9. Alkatout I, Honemeyer U, Strauss A, et al. Clinical diagnosis and treatment of ectopic pregnancy. Obstetrical & Gynecological Survey. 2013;68(8):571–581. PMID 25300511
10. Bachman EA, Barnhart K. Medical management of ectopic pregnancy: a comparison of regimens. Clinical Obstetrics and Gynecology. 2012;55(2):440–447. PMID 24196483
11. Clayton HB, Schieve LA, Peterson HB, Jamieson DJ, Reynolds MA, Wright VC. Ectopic pregnancy risk with assisted reproductive technology procedures. Obstetrics & Gynecology. 2006;107(3):595–604. PMID 16731892
12. Farquhar CM. Ectopic pregnancy. Lancet. 2005;366(9485):583–591. PMID 19501392

Back to Table of Contents

Connections

• Preeclampsia
• Gestational Diabetes
• Infertility
• Endometriosis
• Gestational Trophoblastic Disease
• Hyperemesis Gravidarum
• Reproductive Medicine

Back to Table of Contents

Featured Videos